CLINICAL TRIALS PROFILE FOR ELUXADOLINE

All Clinical Trials for ELUXADOLINE

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT01130272 ↗	Efficacy, Safety, and Tolerability of JNJ-27018966 (Eluxadoline) in the Treatment of Irritable Bowel Syndrome With Diarrhea	Completed	Furiex Pharmaceuticals, Inc	Phase 2	2010-04-28	The purpose of this study is to determine the efficacy, safety, and tolerability of different doses of JNJ-27018966 (eluxadoline) compared with placebo in the treatment of patients with irritable bowel syndrome with diarrhea (IBS-d).
NCT01553591 ↗	Efficacy, Safety, and Tolerability of Eluxadoline in the Treatment of Participants With Diarrhea-Predominant Irritable Bowel Syndrome (IBS-d)	Completed	Furiex Pharmaceuticals, Inc	Phase 3	2012-05-29	The purpose of this study is to determine the efficacy, safety, and tolerability of different doses of eluxadoline (JNJ-27018966) compared with placebo in the treatment of participants with diarrhea-predominant irritable bowel syndrome.
NCT01553747 ↗	Efficacy, Safety, and Tolerability of Eluxadoline in the Treatment of Participants With Diarrhea-Predominant Irritable Bowel Syndrome (IBS-d)	Completed	Furiex Pharmaceuticals, Inc	Phase 3	2012-05-29	The purpose of this study is to determine the efficacy, safety, and tolerability of different doses of eluxadoline (JNJ-27018966) compared with placebo in the treatment of participants with diarrhea-predominant irritable bowel syndrome.
NCT02959983 ↗	Efficacy of Eluxadoline in the Treatment of Irritable Bowel Syndrome With Diarrhea in Patients With Inadequate Control of Symptoms With Prior Loperamide Use	Completed	Allergan	Phase 4	2016-10-25	This study will evaluate the efficacy and safety of eluxadoline 100 milligrams (mg) twice a day (BID) versus placebo for the treatment of patients with Irritable Bowel Syndrome with Diarrhea (IBS-D) who report that the use of loperamide in the prior 12 months failed to provide control of their IBS-D symptoms.
NCT03339128 ↗	Study to Explore the Therapeutic Effect of Eluxadoline in Treating Irritable Bowel Syndrome With Diarrhea in Children	Recruiting	Allergan	Phase 2	2017-11-15	The primary objectives of this study are to explore the therapeutic effect of eluxadoline in treating irritable bowel syndrome with diarrhea (IBS-D) in pediatric participants 6-17 years of age, to evaluate the pharmacokinetics of eluxadoline in pediatric participants with IBS-D, and to evaluate the safety and tolerability of eluxadoline in pediatric participants with IBS-D.
NCT03441581 ↗	Eluxadoline Bile Acid Malabsorption (BAM) Study	Completed	Allergan	Phase 4	2018-02-23	This study will evaluate the possibility of a differential effect of eluxadoline on altered bowel function in Irritable Bowel Syndrome with Diarrhea (IBS-D) participants with and without evidence of Bile Acid Malabsorption (BAM).

Clinical Trial Conditions for ELUXADOLINE

Condition Name

Condition Name for ELUXADOLINE
Intervention	Trials
Irritable Bowel Syndrome	5
Diarrhea	2
Irritable Bowel Syndrome With Diarrhea	2
Diabetic Diarrhea	1

Condition MeSH

Condition MeSH for ELUXADOLINE
Intervention	Trials
Diarrhea	9
Syndrome	7
Irritable Bowel Syndrome	7
Urinary Incontinence, Urge	1

Clinical Trial Locations for ELUXADOLINE

Trials by Country

Trials by Country for ELUXADOLINE
Location	Trials
United States	176
Canada	11
United Kingdom	11
Poland	4
Italy	2

Trials by US State

Trials by US State for ELUXADOLINE
Location	Trials
Oklahoma	6
Florida	5
Pennsylvania	5
Arizona	5
Arkansas	5

Clinical Trial Progress for ELUXADOLINE

Clinical Trial Phase

Clinical Trial Phase for ELUXADOLINE
Clinical Trial Phase	Trials
Phase 4	2
Phase 3	3
Phase 2/Phase 3	1

Clinical Trial Status

Clinical Trial Status for ELUXADOLINE
Clinical Trial Phase	Trials
Completed	5
Recruiting	3
Withdrawn	1

Clinical Trial Sponsors for ELUXADOLINE

Sponsor Name

Sponsor Name for ELUXADOLINE
Sponsor	Trials
Allergan	5
Furiex Pharmaceuticals, Inc	3
University of North Carolina, Chapel Hill	1

Sponsor Type

Sponsor Type for ELUXADOLINE
Sponsor	Trials
Industry	8
Other	2